JSA is advising Equirus Capital Private Limited, Ambit Private Limited and Nuvama Wealth Management Limited (formerly known as Edelweiss Securities Limited) in relation to the proposed initial public offering of equity shares of Senores Pharmaceuticals Limited (“IPO”) comprising a fresh issue of up to INR 5 billion and an offer for sale aggregating up to 2,700,000 Equity Shares by certain Selling Shareholders. Senores Pharmaceuticals Limited has filed its draft red herring prospectus with SEBI on July 26, 2024.
Deal value: Fresh Issue of INR 5 billion and Offer for Sale of 2,700,000 Equity Shares
Our Transaction Team Comprised Lead Partner – Arka Mookerjee, Partner – Siddhartha Desai, Senior Associate – Akash Joshi, Associates – Govind Roy, Anvita Sinha, Reshmi Prabhakar and Ankesh Kumar.
Arka Mookerjee is a Partner and Co-Head of the Equity Capital Markets practice, with over 21 years of experience advising on India’s most complex and high-value transactions. Widely recognised for pioneering mandates—including India’s first QIP and InvIT IPO—he represents issuers, underwriters and investors across capital markets and investment structures. Arka actively engages with regulators and industry bodies, playing a key role in shaping India’s evolving capital markets framework.
Siddhartha specializes in public and private Capital Market transactions. He has advised various issuers, underwriters and selling shareholders on equity offerings such as initial public offerings, rights issues, qualified institutions placements, institutional placement programmes & infrastructure investment trusts (InvITs), and debt offerings such as non-convertible debenture issuances.